| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP1-28667SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-428SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27416 | |||
| BSA Free | NB100-56712SS | |||
| Azide and BSA Free | NBP2-27416SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2214SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-174SS | |||
| Azide and BSA Free | NBP2-80897 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-1936SS | |||
| Azide and BSA Free | NBP2-80955 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-71648SS | |||
| Azide and BSA Free | NBP2-80858 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-654SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-49672SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50037SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB200-598SS | |||
| Azide and BSA Free | NBP2-80928 | |||
![Immunohistochemistry: Olig2 Antibody [NBP1-28667] - Mouse cerebral microslice section (coronal, P14) was co-immunostained with anti-Olig2 and anti-NeuN antibodies. Green: Olig2, Red: NeuN. Anti-Olig2 was used at a 1:800 dilution. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/Olig2-Antibody-Immunohistochemistry-NBP1-28667-img0005.jpg "Immunohistochemistry: Olig2 Antibody [NBP1-28667] - Mouse cerebral microslice section (coronal, P14) was co-immunostained with anti-Olig2 and anti-NeuN antibodies. Green: Olig2, Red: NeuN. Anti-Olig2 was used at a 1:800 dilution. This image was submitted via customer Review.")
![Immunocytochemistry/Immunofluorescence: Olig2 Antibody [NBP1-28667] - Rat cortical neuroepithelial cells with anti-Olig2 (red). The cells were treated with basic FGF for 30 hours prior to staining (this induces Olig2 expression in these primary cells).](http://images.novusbio.com/fullsize/Olig2-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-28667-img0004.jpg)
![Immunohistochemistry-Frozen: Olig2 Antibody [NBP1-28667] - Mouse brain cortex. Antibody at 1:300. Purple: Olig2. Green: CD31. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Olig2-Antibody-Immunohistochemistry-Frozen-NBP1-28667-img0006.jpg)
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Analysis of astrocytes lysate from Rat brain using FIH-1/HIF-1AN antibody at 1:500 dilution with ECL detection. The antibody detected a major band at ~40 kDa position representing FIH-1/HIF-1AN protein.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0007.jpg "Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Analysis of astrocytes lysate from Rat brain using FIH-1/HIF-1AN antibody at 1:500 dilution with ECL detection. The antibody detected a major band at ~40 kDa position representing FIH-1/HIF-1AN protein.")
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Representative picture of western blot in histopathologically unchanged tissue (N) and primary cancerous tissue (C) from patients with CRC. Immunodetection of bands was performed with Rp anti- PHD1 (Catalog # NB100-310), - PHD2 (Catalog # NB100-137), - PHD3 (Catalog # NB100-139) and -FIH-1/HIF-1AN Ab (Catalog # NB100-139), followed by incubation with goat anti-rabbit HRP-conjugated Ab. The membrane was stripped and incubated with Rp anti-GAPDH Ab, followed by incubation with goat anti-rabbit HRP-conjugated Ab. Image collected and cropped by CiteAb from the following publication (//bmccancer.biomedcentral.com/articles/10.1186/1471-2407-13-526), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0010.jpg)
![Immunohistochemistry: FIH-1/HIF-1AN Antibody [NB100-428] - Detection of FIH-1 in rat brain tissue.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Immunohistochemistry-NB100-428-img0008.jpg)
![Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - Rat VSMC (vascular smoot muscle) cells treated (siFIH) or not (CTL) with a specific siRNA against FIH-1. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN-Antibody-Western-Blot-NB100-428-img0009.jpg)
![<b>Biological Strategies Validation and Genetic Strategies Validation.</b>Western Blot: FIH-1/HIF-1AN Antibody [NB100-428] - (C) Cytoplasmic FIH-1 (lower band) and MMP14 expression levels in both aerobic and hypoxic conditions in the 3 cell lines. (E) siRNA targeting FIH-1 was used to assess whether FIH-1 had any effect on CAIX expression in MCF-7 cells cultured in 0.5% O2 conditions. cont, control. m, transfection reagent alone. scr, scrambled siRNA. pool, mixture of 4 siRNAs targeting FIH-1. 21, single siRNA targeting FIH-1. (F) FIH-1 and CAIX expression levels in aerobic MCF-7 cells treated with either siRNA against FIH-1 alone, or both 400 uM CoCl2 and siRNA together for 24, 48 and 72h. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28476026/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/FIH-1-HIF-1AN Antibody-Knockdown Validated-NB100-428-img0011.jpg)
![Immunohistochemistry: FIH-1/HIF-1AN Antibody [NB100-428] - 3D target protein expression in multicellular tumor spheroids3D expression analysis was carried out in the MCF-7, MDA-MB-231 & HBL-100 cell lines using multicellular tumor spheroids. The spheroids were cultured in spinner flasks for 1 week before fixation. Hypoxyprobe was used to examine the formation of hypoxic areas within the spheroids. NHE1, CAIX, MMP14 & FIH-1 expression was also analyzed. Incubation for an hour with PBS instead of primary antibody acted as a control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17143), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-428_rabbit-polyclonal-fih-1-hif-1an-antibody-310202415384122.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0013.jpg "Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Analysis of P65 using p65 antibody at 2 ug/mL in 30 ug of A) Ramos, B) Daudi, C) HeLa and D) mouse NIH 3T3 cell lysate.")
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lane view shows a specific band for NFkB p65 in 1.0 mg/mL of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0006.jpg)
![Western Blot: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Lysates of HeLa human cervical epithelial carcinoma cell line and Daudi human Burkitt's lymphoma cell line. PVDF membrane was probed with 1 ug/mL mouse anti-RelA/NFkB p65 monoclonal (NB100-56712, Novus Biologicals), followed by 1:2000 dilution of the appropriate HRP-conjugated secondary antibody, donkey anti-mouse IgG (HAF018).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Western-Blot-NB100-56712-img0016.jpg)
![Immunohistochemistry-Paraffin: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Ovarian cystadenocarcinoma probed with p65 antibody at 5 ug/mL. Human tissue TMA was used for this test. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Immunohistochemistry-Paraffin-NB100-56712-img0009.jpg)
![Flow Cytometry: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Intracellular staining of 293 HEK cells using 0.5 ug of p65 antibody. Green histogram represents the isotype control (p65) antibody. This NFkB p65 antibody was used for this test with an anti-mouse IgG PE conjugated secondary antibody.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Flow-Cytometry-NB100-56712-img0004.jpg)
![Simple Western: RelA/NFkB p65 Antibody (112A1021) [NB100-56712] - Detection of p65 by Simple Western (JESS) in chemiluminescence in nuclear extract of reconstructed human epidermis lysate (about 600 ug/mL protein concentration).Antibody at 1:20. Simple Western image submitted by a verified customer review.](http://images.novusbio.com/fullsize/RelA-NFkB-p65-Antibody-112A1021-Simple-Western-NB100-56712-img0017.jpg)
![Western Blot: Jumonji/JARID2 Antibody [NB100-2214] - Jumonji/JARID2 N-terminus mediates direct interaction with H2AK119u1-modified nucleosomes. Immunoblot of nucleosomal pull downs from nuclear extract. Total nuclear extract (input) and pull down using streptavidin beads, unmodified nucleosomes or nucleosomes modified by H2AK119u1/H2AK119u1(I44A) were probed with the indicated antibodies using extracts from WT cells (left) or Jumonji/JARID2 KO mESCs (right). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms13661) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Jumonji-JARID2-Antibody-Knockout-Validated-NB100-2214-img0009.jpg "<b>Genetic Strategies Validation. </b>Western Blot: Jumonji/JARID2 Antibody [NB100-2214] - Jumonji/JARID2 N-terminus mediates direct interaction with H2AK119u1-modified nucleosomes. Immunoblot of nucleosomal pull downs from nuclear extract. Total nuclear extract (input) and pull down using streptavidin beads, unmodified nucleosomes or nucleosomes modified by H2AK119u1/H2AK119u1(I44A) were probed with the indicated antibodies using extracts from WT cells (left) or Jumonji/JARID2 KO mESCs (right). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms13661) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Jumonji/JARID2 Antibody [NB100-2214] - JARID2 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/Jumonji-JARID2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2214-img0001.jpg)
![Western Blot: Jumonji/JARID2 Antibody [NB100-2214] - Jarid2 expression in naive and activated (overnight) murine B cells. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/Jumonji-JARID2-Antibody-Western-Blot-NB100-2214-img0008.jpg)
![Immunohistochemistry-Paraffin: Jumonji/JARID2 Antibody [NB100-2214] - Tested in mouse brain using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/Jumonji-JARID2-Antibody-Immunohistochemistry-Paraffin-NB100-2214-img0006.jpg)
![Western Blot: Jumonji/JARID2 Antibody [NB100-2214] - Detection of JARID2 protein in E16 mouse brain lysate using 2ug/ml of NB100-2214.](http://images.novusbio.com/fullsize/Jumonji-JARID2-Antibody-Western-Blot-NB100-2214-img0005.jpg)
![Simple Western: Jumonji/JARID2 Antibody [NB100-2214] - Simple Western lane view shows a specific band for JARID2 in 0.5 mg/ml of Human Brain lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Jumonji-JARID2-Antibody-Simple-Western-NB100-2214-img0007.jpg)
![Western Blot: Jumonji/JARID2 Antibody [NB100-2214] - JARID2 N-terminus mediates direct interaction with H2AK119u1-modified nucleosomes(a) Immunoblot of nucleosomal pull downs from nuclear extract. Total nuclear extract (input) & pull down using streptavidin beads, unmodified nucleosomes or nucleosomes modified by H2AK119u1/H2AK119u1(I44A) were probed with the indicated antibodies using extracts from WT cells (left) or JARID2 KO mESCs (right). Full blots are shown in Supplementary Fig. 9. (b) JARID2 1–530 binds to H2AK119u1-modified mononucleosomes (yellow) more tightly than unmodified (blue) or H2AK199u1(I44A) (red) as monitored by biolayer interferometry (n=3). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27892467), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2214_rabbit-polyclonal-jumonji-jarid2-antibody-310202415392539.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0011.jpg "Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Staining of sections from a wild type mouse testis taken at P11 were probed with NB200-174 (green). Sections were stained with DAPI to reveal the position of cell nuclei (blue).](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Immunohistochemistry-NB200-174-img0008.jpg)
![Flow (Intracellular): p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - An intracellular stain was performed on HEK293 cells with p14ARF (5-C3-1) antibody NB200-174 (blue) and a matched isotype control MAB0061 (orange) [A]. An intracellular stain was also performed on THP-1 (known homozygous deletion of gene, PMID: 19635138) cells to ensure antibody specificity [B]. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Goat Anti-Rat F(ab)2 IgG (H+L) APC-conjugated Antibody (F0113, R&D Systems). *Note: This antibody recognizes both human (p14ARF) and mouse (p19ARF) versions of the protein.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Flow-Intracellular-NB200-174-img0010.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Aberrantly upregulated p19ARF/CDKN2A antagonizes TFH differentiation and survival. p19ARF/CDKN2A and Bcl6 interaction capacity. WT or mutant p19ARF/CDKN2A was co-transfected with WT Bcl6 expression vector into 293T cells. Cell lysates were immunoprecipitated with anti-Bcl6 and then immunoblotted with anti-p19ARF/CDKN2A. Data are representative of two experiments. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-018-07853-z) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0012.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Analysis of endogenous p19Arf. Total cell lysates (25 ug) from NIH3T3 cells, which have deleted the Arf gene (Lanes 1) and from wild type mouse embryo fibroblasts (MEFs) at passage 6, which express p19Arf (Lanes 2), were resolved by SDS-PAGE.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0005.jpg)
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Detection of p19Arf. Wild type mouse embryo fibroblasts (MEF) at passage 5 (panels 1, 2) and NIH3T3 cells, which have deleted the Arf gene (panels 3, 4) were probed with NB200-17 and nuclear stain (overlay in panels 2 and 4).](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Knockout-Validated-NB200-174-img0009.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Phosphorylation of NPM-Ser48 regulates the localization of NPM & p19A(A) Npm−/−, p53−/−double null MEF were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. Cells were fixed & stained with DAPI & anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates & whole cell lysates from Npm−/−;p53−/− MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed & stained with DAPI, anti-NPM & anti p19ARF. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-31020241621829.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416205122.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Loss of P19Arf enhances tumor growth & primary lung fibroblasts induce p19Arf in response to leucine deprivation (LD). (A) Graph of sarcoma (SKPY) tumor volume on the indicated days. SKPY cells were injected into the flank of WT & p19Arf-null mice. Tumor volume was measured by caliper. N=7 mice/WT cohort & N=15 mice/p19Arf−/− cohort. (B) Western blot for p19Arf protein expression in WT & Arf-null fibroblasts after LD for the indicated days. Densitometric quantification of p19Arf protein expression relative to beta -tubulin is shown on right. (C) qPCR for p19Arf mRNA in WT or p19Arf−/− fibroblasts during LD for the indicated days. (D) Representative immunofluorescence images for P19Arf subcellular localization on the indicated days after LD in WT or p19Arf−/− ALFs. Quantification of nuclear p19Arf is shown in graph on right. (E) Western blot analysis of phospho-eIF2 alpha (P-eIF2 alpha ) & total eIF2 alpha expression in WT & p19Arf-null murine ALFs during LD for the indicated days. Graph quantifies intensity of P-eIF2 alpha expression relative to day 0. beta -Tubulin used as loading control. (F) Western blot analysis of P-eIF2 alpha expression in WT & p19Arf−/− ALFs upon treatment with a GCN2 inhibitor (GCN2-IN-1; A-92 1 µM in DMSO) during overnight LD. Actin used as a loading control. Quantification of P-eIF2 alpha expression relative to total eIF2 alpha . N=3; *, P<0.05; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34994382), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416205128.jpg)
![Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Phosphorylation of NPM-Ser48 regulates the localization of NPM & p19A(A) Npm−/−, p53−/−double null MEF were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. Cells were fixed & stained with DAPI & anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates & whole cell lysates from Npm−/−;p53−/− MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed & stained with DAPI, anti-NPM & anti p19ARF. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416203717.jpg)
![Flow Cytometry: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free - Conducted the antibody trial with two different dilutions of p19ARF/CDKN2A Antibody (5-C3-1) [PE] (Catalog # NB200-174PE) (1:500 and 1:100) and compared them to an IgG control which was also PE labelled. Image from a verified customer review.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-312202414314910.png)
![Immunohistochemistry: SMN Antibody (2B1) [NB100-1936] - CBs lose their colocalization with SMN nuclear foci in diabetic mice. Normal and pathological distribution of SMN proteins in sensory neurons. SMN proteins were found throughout the cytoplasm and as nuclear foci in control sensory neurons. SMN nuclear foci localized within CBs (coilin) in controls (upper panels, white arrows), whereas in the diabetic nucleus the numerous CBs were present but lost their colocalization with SMN nuclear foci (lower panels, yellow arrows). Arrowheads indicate sensory neurons magnified in the insets. Scale bars: 20 um, 10 um in insets. Image collected and cropped by CiteAb from the following publication (//dmm.biologists.org/lookup/doi/10.1242/dmm.028225), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Immunohistochemistry-NB100-1936-img0007.jpg "Immunohistochemistry: SMN Antibody (2B1) [NB100-1936] - CBs lose their colocalization with SMN nuclear foci in diabetic mice. Normal and pathological distribution of SMN proteins in sensory neurons. SMN proteins were found throughout the cytoplasm and as nuclear foci in control sensory neurons. SMN nuclear foci localized within CBs (coilin) in controls (upper panels, white arrows), whereas in the diabetic nucleus the numerous CBs were present but lost their colocalization with SMN nuclear foci (lower panels, yellow arrows). Arrowheads indicate sensory neurons magnified in the insets. Scale bars: 20 um, 10 um in insets. Image collected and cropped by CiteAb from the following publication (//dmm.biologists.org/lookup/doi/10.1242/dmm.028225), licensed under a CC-BY license.")
![Western Blot: SMN Antibody (2B1) [NB100-1936] - Analysis of SMN expression in 1) HeLa, 2) NTera2, 3) HepG2, 4) MCF7, 5) NIH 3T3, 6) PC12, and 7) COS7 whole cell lysates.](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Western-Blot-NB100-1936-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: SMN Antibody (2B1) [NB100-1936] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NB100-1936 at 2 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Immunocytochemistry-Immunofluorescence-NB100-1936-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: SMN Antibody (2B1) [NB100-1936] - scIF of control (f) and etv5b MO (g) cells from pmnx1:eGFP embryos. H2B, GFP and Smn signals are shown in Z-projected confocal sections. GFP+ cells marked by white rectangles are magnified on the right. Scale bars: 10 um for low and 5 um for high magnification. Image collected and cropped by Citeab from the following publication (Transcriptional enhancement of Smn levels in motoneurons is crucial for proper axon morphology in zebrafish. Sci Rep (2016) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Immunocytochemistry-Immunofluorescence-NB100-1936-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: SMN Antibody (2B1) [NB100-1936] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with SMN Antibody [2B1] conjugated to Alexa Fluor 488 (NB100-1936AF488) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Immunocytochemistry-Immunofluorescence-NB100-1936-img0012.jpg)
![Flow Cytometry: SMN Antibody (2B1) [NB100-1936] - An intracellular stain was performed on Neuro2a cells with SMN Antibody (2B1) NB100-1936 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Flow-Cytometry-NB100-1936-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: SMN Antibody (2B1) [NB100-1936] - The SMN antibody was tested at a 1:250 dilution in HeLa cells against DyLight 488 (Green). Actin nuclei were counterstained against Phalloidin 568 (Red) and DAPI (Blue), respectively.](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Immunocytochemistry-Immunofluorescence-NB100-1936-img0004.jpg)
![Immunohistochemistry: SMN Antibody (2B1) [NB100-1936] - Analysis of SMN on mouse brain using NB100-1936.](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Immunohistochemistry-NB100-1936-img0001.jpg)
![Flow Cytometry: SMN Antibody (2B1) [NB100-1936] - An intracellular stain was performed on Ntera2 cells with SMN Antibody (2B1) NB100-1936 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/SMN-Antibody-2B1-Flow-Cytometry-NB100-1936-img0008.jpg)
![Immunocytochemistry/ Immunofluorescence: SMN Antibody (2B1) [NB100-1936] - CWC22 is colocalized with nuclear speckles & upregulated in diabetic DRG sensory neurons. (A) Subcellular distribution of TDP-43 & CWC22 in control DRG sensory neurons. TDP-43 was stained diffusely in the nucleus, excluding SMN foci in sensory neurons. CWC22 consistently colocalized with a marker protein SC35 of nuclear speckles in sensory neurons. No obvious differences in the subcellular localization of CWC22 were identified in diabetic neurons (not shown) compared with controls. Scale bar: 10 μm. (B) qRT-PCR analysis of Cwc22 mRNA expression in diabetic & control mice. Cwc22 expression was upregulated ∼2.5-fold in diabetic DRGs. *P<0.05, unpaired two-tailed Student's t-test. Data represented as mean±s.e.m. See Cheng et al. (2015) for microarray data indicating rises in Cwc22 expression as reported separately. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/dmm/article/10/3/215/2257/Diabetic-polyneuropathy-sensory-neurons-nuclear), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1936_mouse-monoclonal-smn-antibody-2b1-3102024168396.jpg)
![Simple Western: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Simple Western lane view shows a specific band for mtTFA in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Simple-Western-NBP1-71648-img0008.jpg "Simple Western: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Simple Western lane view shows a specific band for mtTFA in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![<b>Genetic Strategies Validation. </b>Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - MtDNA depletion and reversible impaired immune functions in THP-1A cells. A and B, Treatment with 50A ng/mL ethidium bromide (EtBr) for 8A weeks. Transfection with 30A nmol/L negative or TFAM siRNA for 8A days. TFAM protein relative toI2-actin. D, MtDNA levels. E, LPS-induced TNF-I+-and IL-8 release. Image collected and cropped by Citeab from the following publication (Mitochondrial DNA depletion induces innate immune dysfunction rescued by IFN-g. J Allergy Clin Immunol (2017)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Western-Blot-NBP1-71648-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: mtTFA Antibody (18G102B2E11) [NBP1-71648] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-mtTFA Antibody (18G102B2E11) NBP1-71648 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunocytochemistry-Immunofluorescence-NBP1-71648-img0014.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Induction of mitochondrial biogenesis following exposure of THP-1 cells to LPS. THP-1 cells were incubated with LPS (100 ng/ml) for 0AE](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Western-Blot-NBP1-71648-img0013.jpg)
![Immunohistochemistry-Paraffin: mtTFA Antibody (18G102B2E11) [NBP1-71648] - IHC staining of mtTFA on human testis using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunohistochemistry-Paraffin-NBP1-71648-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: mtTFA Antibody (18G102B2E11) [NBP1-71648] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-mtTFA Antibody (18G102B2E11) NBP1-71648 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunocytochemistry-Immunofluorescence-NBP1-71648-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: mtTFA Antibody (18G102B2E11) [NBP1-71648] - NIH3T3 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-mtTFA Antibody (18G102B2E11) NBP1-71648 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunocytochemistry-Immunofluorescence-NBP1-71648-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Immunostaining in HeLa cells. C1: DAPI staining 2 nuclei, C2: anti-mtTFA stain with Alexa Fluor 488 secondary ab (green), C3: Mitotracker Red staining mitochondria. Image courtesy of Elizabeth Wang.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Immunocytochemistry-Immunofluorescence-NBP1-71648-img0003.jpg)
![Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Total protein from Hela and U937 were separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-mtTFA NBP1-71648 in blocking buffer and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Western-Blot-NBP1-71648-img0017.jpg)
![Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Analysis of mtTFA expression in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Western-Blot-NBP1-71648-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - Alcohol feeding significantly decreased TFAM expression in rat liver. This image was submitted by a customer review.](http://images.novusbio.com/fullsize/mtTFA-Antibody-18G102B2E11-Western-Blot-NBP1-71648-img0009.jpg)
![Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - MtDNA depletion & reversible impaired immune functions in THP-1 cells. A & B, Treatment with 50 ng/mL ethidium bromide (EtBr) for 8 weeks. A, MtDNA levels. B, LPS-induced TNF-alpha & IL-8 release. C-E, Transfection with 30 nmol/L negative or TFAM siRNA for 8 days. C, TFAM protein relative to beta -actin. D, MtDNA levels. E, LPS-induced TNF-alpha & IL-8 release. F-H, TFAM recovery 8 days after removal of TFAM siRNA. F, TFAM protein relative beta -actin. G, MtDNA levels. H, LPS-induced TNF-alpha & IL-8 release. All experiments are presented as means ± SD of 3 to 4 independent biological replicates. *P < .05, **P < .01, & ***P < .001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28629747), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-71648_mouse-monoclonal-mttfa-antibody-18g102b2e11-310202415384163.jpg)
![Western Blot: mtTFA Antibody (18G102B2E11) [NBP1-71648] - MtDNA depletion & impaired immune functions & subsequent recovery in THP-1 cells following transfection with TFAM siRNA. A-G, Transfection with TFAM siRNA. A, TFAM proteins levels relative to beta -actin during titration of TFAM siRNA, showing optimal knockdown of TFAM protein after transfection of THP-1 cells with 30 nmol/L siRNA for 8 days. B, Cell viability. C, Cell proliferation. D, The levels of the MT-CO1 & SDHA proteins relative to beta -actin. D, OCR for different aspects of mitochondrial respiration & respiratory profile. E, Phagocytosis of E coli. Recovery 8 days after removal of TFAM siRNA. F, Levels of the MT-CO1 & SDHA proteins relative to beta -actin. G, Oxygen consumption for different aspects of mitochondrial respiration. H, Bacterial phagocytosis. All experiments were carried out on 3 to 4 independent biological replicates & are presented as means ± SD. **P < .01 & ***P < .001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28629747), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-71648_mouse-monoclonal-mttfa-antibody-18g102b2e11-310202416182618.jpg)
![Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of in vitro hypoxia on the expression of mouse HIF-1 alpha in HIF-1 alpha+/- and HIF-1 alpha+/+ astrocytes. Confluent astrocyte monolayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1 alpha mRNA expression was determined by RT-PCR as described in Materials and Methods. Each bar represents the mean +/- SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0009.jpg "<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of in vitro hypoxia on the expression of mouse HIF-1 alpha in HIF-1 alpha+/- and HIF-1 alpha+/+ astrocytes. Confluent astrocyte monolayers of both cell types were exposed to a 6 h in vitro hypoxia. HIF-1 alpha mRNA expression was determined by RT-PCR as described in Materials and Methods. Each bar represents the mean +/- SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisks and number sign indicate significant difference (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.")
![<b>Biological Strategies Validation, Genetic Strategies Validation and Orthogonal Strategies Validation.</b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Effects of CoCl2 treatment on HIF-1 alpha expression in mouse astrocytes. Western blots using nuclear proteins show that both hypoxia (H) and CoCl2 (Co) up-regulated HIF-1 alpha protein in HIF-1 alpha+/+ and HIF-1 alpha+/- cells. There was no HIF-1 alpha protein detected in control cells. Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0008.jpg)
![Immunohistochemistry-Paraffin: HIF-1 alpha Antibody [NB100-654] - IHC analysis of a formalin-fixed paraffin-embedded tissue section of human endometrium carcinoma AN3CA cell line based xenograft using rabbit polyclonal HIF-1 alpha antibody NB100-654 at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the section was further counterstained using hematoxylin. The tested section depicted mainly a diffused cytoplasmic staining but there were some cells which showed nuclear signal also (representing hypoxic cells).](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Immunohistochemistry-Paraffin-NB100-654-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody [NB100-654] - HIF1-alpha analysis using NB100-654. Image submitted from verified customer review.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0007.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HIF-1 alpha Antibody [NB100-654] - Detection of HIF-1 alpha in cobalt chloride treated/untreated COS-7 nuclear extracts using NB100-654.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Western-Blot-NB100-654-img0003.jpg)
![Simple Western: HIF-1 alpha Antibody [NB100-654] - Simple Western lane view shows a specific band for HIF-1 alpha in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Simple-Western-NB100-654-img0005.jpg)
![Gel Super Shift Assays: HIF-1 alpha Antibody [NB100-654] - Mouse HIF-1 alpha+/+ and HIF-1 alpha+/- cells were exposed to hypoxia or 125 uM CoCl2 for 6 h, nuclear extracts were then prepared and EMSA carried out. HIF-1 isolated from hypoxia or CoCl2-treated cells bound to the wild-type probe (lanes #1-6) but not to the mutant probe (lanes #7-12). HIF-1/DNA complex was detected in hypoxia (H)-or CoCl2 (Co)-treated cells (lanes #2, 3, 5, 6) but not in control (C) cells (lanes #1, 4). More complex (darker band) was seen in hypoxia-or CoCl2-treated HIF-1 alpha+/+ cells (lanes #2, 3) than that in hypoxia-or CoCl2-treated HIF-1 alpha+/- cells (lanes #5, 6). Supershift assay showed that the HIF-1/DNA complex was shifted up in the presence of wild-type (wt) oligo probe and 4 ug HIF-1 alpha antiboby (lanes #13 & 14). Image collected and cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-4-12), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HIF-1-alpha-Antibody-Gel-Super-Shift-Assays-NB100-654-img0011.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Effects of CoCl2 treatment on HIF-1 alpha expression in mouse astrocytes. (A) The cells were incubated in the presence or absence of 125 μM CoCl2 for 6 hr. HIF-1 alpha mRNA expression was determined by RT-PCR. Each bar represents the mean ± SD of relative density/volumes of the bands on film negatives from at least three experiments. Asterisk & number sign indicate significant difference compared to relevant controls (p < 0.01; one-way ANOVA, followed by multiple comparisons among means). (B) Western blots using nuclear proteins show that both hypoxia (H) & CoCl2 (Co) up-regulated HIF-1 alpha protein in HIF-1 alpha +/+ & HIF-1 alpha +/- cells. There was no HIF-1 alpha protein detected in control cells (C). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/17474992), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241529191.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241553714.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241682154.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-310202415523946.jpg)
![Western Blot: HIF-1 alpha Antibody - BSA Free [NB100-654] - Aberrant HIF1 alpha expression in PDAC cancer associated fibroblastsA. The level of MCT4 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. B. The level of MCT1 was determined in the indicated established pancreatic cancer cell lines & CAF cultures by immunoblotting. C. HIF alpha & MCT4 levels were determined by immunoblotting following the knockdown of HIF1 alpha with RNAi or the induction of hypoxia through the use of CoCl2. D. The stability of HIF1 alpha was evaluated in CAFs following treatment with cycloheximide. E. HIF1 alpha was detected by immunoblotting in the presence of cycloheximide in the absence or presence of the proteasome inhibitor MG132. F. HIF1 alpha protein levels were determined in the absence & presence of DMOG. G. RNA levels of the indicated genes as determined by microarray analyses (**p < 0.01 for tumor cell line vs. CAF). H. MG132 was used to interrogate the synthetic rate of HIF1 alpha protein in the indicated cell lines. I. The expression of HIF1 alpha target genes was evaluated in the indicated cell lines by microarray analysis (**p < 0.01 for tumor cell vs. CAF). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27623078), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-654_rabbit-polyclonal-hif-1-alpha-antibody-31020241553515.jpg)
![Western Blot: NKX6.1 Antibody [NBP1-49672] - Analysis of Nkx6.1 in human skeletal muscle.](http://images.novusbio.com/fullsize/NKX6.1-Antibody-Western-Blot-NBP1-49672-img0004.jpg "Western Blot: NKX6.1 Antibody [NBP1-49672] - Analysis of Nkx6.1 in human skeletal muscle.")
![Immunocytochemistry/Immunofluorescence: NKX6.1 Antibody [NBP1-49672] - Nkx6.1 antibody was tested at 1:250 in INS-1 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red). Image objective 40X.](http://images.novusbio.com/fullsize/NKX6.1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-49672-img0006.jpg)
![Immunohistochemistry: NKX6.1 Antibody - BSA Free [NBP1-49672] - A) Representative immunofluorescence images of pancreatic sections with NKX6.1 and Insulin (Ins). B) Relationships among different dedifferentiated beta cell labeled by white boxes in (a). Scale bars: 20 um, Red: NKX6.1, Green: Ins, Blue: DAPI. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33711989/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NKX6.1-Antibody---BSA-Free-Immunohistochemistry-NBP1-49672-img0012.jpg)
![Immunohistochemistry-Frozen: NKX6.1 Antibody [NBP1-49672] - Analysis of NKX6.1 in mouse pancreas frozen tissue section using anti-NKX6.1 antibody. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX6.1-Antibody-Immunohistochemistry-Frozen-NBP1-49672-img0009.jpg)
![Immunohistochemistry: NKX6.1 Antibody [NBP1-49672] - Staining of Nkx6.1 in mouse intestine using DAB with hematoxylin counterstain.](http://images.novusbio.com/fullsize/NKX6.1-Antibody-Immunohistochemistry-NBP1-49672-img0003.jpg)
![Immunohistochemistry-Paraffin: NKX6.1 Antibody [NBP1-49672] - Human fetal pancreas stained for Nkx6.1, green, and PDX1, grey. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX6.1-Antibody-Immunohistochemistry-Paraffin-NBP1-49672-img0007.jpg)
![Immunohistochemistry-Paraffin: NKX6.1 Antibody [NBP1-49672] - Mouse pancreas tissue. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX6.1-Antibody-Immunohistochemistry-Paraffin-NBP1-49672-img0010.jpg)
![Immunohistochemistry-Paraffin: NKX6.1 Antibody [NBP1-49672] - Paraffin embeded rat pancreatic tissue at 40x resolution stained for insulin (red) and NKX6.1 (NBP1-49672, green). IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/NKX6.1-Antibody-Immunohistochemistry-Paraffin-NBP1-49672-img0011.jpg)
![Simple Western: NKX6.1 Antibody [NBP1-49672] - Image shows a specific band for NKX6.1 in 0.5 mg/mL of BTC-6 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/NKX6.1-Antibody-Simple-Western-NBP1-49672-img0008.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0003.jpg "<b>Biological Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Section of rat hippocampus stained with mouse monoclonal antibody to c-FOS NBP2-50037 in red and counterstained with rabbit polyclonal antibody to FOX3/NeuN. DAPI reveals nuclei of neurons and glia in blue. The hippocampal neurons stain green for FOX3/NeuN and a few also are expressing c-FOS, and so appear orange. These cells were spontaneously active at the time the animal was sacrificed.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and c-Fox knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1000 of Mouse Anti-Human c-Fox Monoclonal Antibody (Catalog # NBP2-50037) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for c-Fox at approximately 52 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Knockout-Validated-NBP2-50037-img0005.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Analysis of cell lysates using mouse c-Fos mAb, dilution 1:1,000 (Green), and rabbit GAPDH pAb, dilution 1:20,000 (Red) used as a loading control. [1] protein standard (red), [2] HeLa cells in serum free media. [3] HeLa cells stimulated with 20% fetal bovine serum for 2hrs after 36hrs in serum free media. [4] rat cortical neurons. [5] rat cortical neurons treated with membrane depolarization buffer for 5hrs. Multiple bands at 50-65kDa in stimulated or treated cell lysates correspond to different forms of the c-Fos proten. The single band at 37 kDa represents GAPDH protein.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0007.jpg)
![Immunohistochemistry: c-Fos Antibody (2H2) [NBP2-50037] - pAb 1:1000 (green), DAPI counterstain (blue) on 30 micron cryosection of mouse spinal cord. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-NBP2-50037-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Left: NBP2-50037 staining (green) in HeLa cells, which were treated with serum-starvation for 36 hrs, followed by 2 hrs 20% FBS stimulation (bottom), or PBS treatment (top). Green c-Fos staining only localizes in the nuclei of stimulated cells, but not in un-stimulated cells. Cells are counter-stained with chicken pAb against Vimentin (NB300-223, red). Blue shows DAPI staining of nucleus. Middle: Mouse brain section (45 uM; fixed by transcardial perfusion with 4% PFA) labeled with NBP2-50037 using a standard HRP-DAB staining technique. Cells expressing c-Fos show dark color in nucleus. Right: Mouse cortical section labeled with NBP2-50037 (red) and rabbit polyclonal anti-NeuN (NBP1-92716, green) using IF confocal. Neurons positive for c-Fos and RBFOX3/NeuN appear to be yellow. Inset shows an enlarged image of NBP2-50037 staining. Nuclei are labeled with Dapi (blue).](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0001.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: RNA Polymerase II/POLR2A Antibody (4H8) [NB200-598] - Whole cell protein from HeLa (lane 1), MCF7 (lane 2), NIH-3T3 (lane 3) and Cos7 (lane 4) were separated by SDS-PAGE on a 6% gel, transferred to PVDF and probed with 2 ug/mL NB200-598. RNA Pol II reactivity (arrowhead) is observed in HeLa, MCF and 3T3 cells.](http://images.novusbio.com/fullsize/RNA-Polymerase-II-POLR2A-Antibody-4H8-Western-Blot-NB200-598-img0010.jpg "Western Blot: RNA Polymerase II/POLR2A Antibody (4H8) [NB200-598] - Whole cell protein from HeLa (lane 1), MCF7 (lane 2), NIH-3T3 (lane 3) and Cos7 (lane 4) were separated by SDS-PAGE on a 6% gel, transferred to PVDF and probed with 2 ug/mL NB200-598. RNA Pol II reactivity (arrowhead) is observed in HeLa, MCF and 3T3 cells.")
![Immunocytochemistry/Immunofluorescence: RNA Polymerase II/POLR2A Antibody (4H8) [NB200-598] - RNA Polymerase II/POLR2A antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/RNA-Polymerase-II-POLR2A-Antibody-4H8-Immunocytochemistry-Immunofluorescence-NB200-598-img0011.jpg)
![Flow Cytometry: RNA Polymerase II/POLR2A Antibody (4H8) [NB200-598] - An intracellular stain was performed on HeLa cells with RNA Polymerase II/POLR2A (4H8) antibody NB200-598PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/RNA-Polymerase-II-POLR2A-Antibody-4H8-Flow-Cytometry-NB200-598-img0013.jpg)
![Western Blot: RNA Polymerase II/POLR2A Antibody (4H8) [NB200-598] - Analysis of MCF7 cell lysata (A) using RNA polymerase II antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/RNA-Polymerase-II-POLR2A-Antibody-4H8-Western-Blot-NB200-598-img0009.jpg)
![Flow (Intracellular): RNA Polymerase II/POLR2A Antibody (4H8) [NB200-598] - An intracellular stain was performed on Daudi cells with RNA Polymerase II/POLR2A (4H8) antibody NB200-598 (blue) and a matched isotype control NBP2-27287 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/RNA-Polymerase-II-POLR2A-Antibody-4H8-Flow-Intracellular-NB200-598-img0012.jpg)